Patent ID: 11858995
Assignee: GENMAB A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 25:
26. A method of treating chronic lymphocytic leukemia (CLL) in a human subject, the method comprising subcutaneously administering epcoritamab to the subject at a dose ranging from 12-60 mg in 28-day cycles, wherein:
a) in cycle 1, a priming dose of 0.16 mg is administered on day 1, an intermediate dose of 0.8 mg on day 8, and a full dose of 12-60 mg on days 15 and 22;
b) in cycles 2-3, a full dose of 12-60 mg is administered on days 1, 8, 15, and 22;
c) in cycles 4-9, a full dose of 12-60 mg is administered on days 1 and 15; and
d) in cycle 10 and subsequent cycles, a full dose of 12-60 mg is administered on day 1, wherein administration of the full dose of the bispecific antibody continues at least until the subject exhibits a complete response (CR), a partial response (PR) or stable disease, or until progressive disease develops or unacceptable toxicity occurs.